invoX CEO Ben Toogood (L) and F-star CEO Eliot Forster
July 8, 2022 09:17 AM EDTUpdated 03:02 PM
Deals
Bioregnum

A por­trait of a biotech buy­out deal in sav­age times: turn­ing a $15.50 of­fer in­to a $7.12 deal

Back last No­vem­ber, the once high-fly­ing F-star was hurt­ing, bad. Its share price had been crushed and the CEO, Eliot Forster of Im­muno­core fame, had …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Re­gen­eron plans to buy 23andMe for $256M

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times